Agriculture business drives successful start to year: Bayer
The CEO reiterated earlier guidance for 2022 core earnings per share to reach about 7.00 euros, up from 6.51 euros last year, excluding the effect of currency swings.
Frankfurt: German diversified group Bayer has seen a "very successful start to the year", driven by favourable agricultural markets, it said on Monday."In the agriculture business, in particular, we see a much more positive market environment than in previous years," Chief Executive Werner Baumann said in a written speech posted on the company's website on Monday.The speech will be delivered...
Frankfurt: German diversified group Bayer has seen a "very successful start to the year", driven by favourable agricultural markets, it said on Monday.
"In the agriculture business, in particular, we see a much more positive market environment than in previous years," Chief Executive Werner Baumann said in a written speech posted on the company's website on Monday.
The speech will be delivered at the annual shareholder meeting scheduled for Friday.
The maker of pharmaceuticals, seeds and pesticides added the economic consequences of the war in Ukraine and sanctions imposed on Russia were not yet visible in the first quarter.
The CEO reiterated earlier guidance for 2022 core earnings per share to reach about 7.00 euros ($7.50), up from 6.51 euros last year, excluding the effect of currency swings.
Read also: Bayer launches campaign 'Preserve The Uterus' to stall untimely hysterectomies in India
Baumann added that despite global uncertainties he was confident of a very successful year.
Bayer is due to release detailed first-quarter figures on May 10.
Read also: Bayer appoints Tara Frenkl as new head of oncology development at oncology strategic business unit
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd